Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference

The American Journal of Medicine
Sripal BangaloreFranz H Messerli


Dry cough is a common, annoying adverse effect of all angiotensin-converting enzyme (ACE) inhibitors. The present study was designed to compare the rate of coughs reported in the literature with reported rates in the Physicians' Desk Reference (PDR)/drug label. We searched MEDLINE/EMBASE/CENTRAL for articles published from 1990 to the present about randomized clinical trials (RCTs) of ACE inhibitors with a sample size of at least 100 patients in the ACE inhibitors arm with follow-up for at least 3 months and reporting the incidence or withdrawal rates due to cough. Baseline characteristics, cohort enrolled, metrics used to assess cough, incidence, and withdrawal rates due to cough were abstracted. One hundred twenty-five studies that satisfied our inclusion criteria enrolled 198,130 patients. The pooled weighted incidence of cough for enalapril was 11.48% (95% confidence interval [CI], 9.54% to 13.41%), which was ninefold greater compared to the reported rate in the PDR/drug label (1.3%). The pooled weighted withdrawal rate due to cough for enalapril was 2.57% (95% CI, 2.40-2.74), which was 31-fold greater compared to the reported rate in the PDR/drug label (0.1%). The incidence of cough has increased progressively over the las...Continue Reading


Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jan 1, 1994·The American Journal of Medicine·H M PerryM Sirgo
Sep 1, 1995·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·T SarutaK Ito
Dec 1, 1996·Journal of Cardiovascular Pharmacology·M StimpelI Loh
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jan 24, 1998·Clinical and Experimental Hypertension : CHE·A D BremnerF Bodin
Feb 19, 1998·Journal of Human Hypertension·L Van NuetenJ I Robertson
Mar 26, 1998·Journal of Cardiovascular Pharmacology·S G Chrysant, M Stimpel
May 5, 1999·Journal of Cardiovascular Pharmacology·J Cosín-AguilarE Marin-Huerta
Jul 29, 1999·American Journal of Therapeutics·J M NeutelG Guthrie
Oct 9, 1999·Hypertension Research : Official Journal of the Japanese Society of Hypertension·T SarutaM Nakajima
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais

❮ Previous
Next ❯


Oct 8, 1999·European Journal of Drug Metabolism and Pharmacokinetics·M C NahataR W Force
Jul 14, 2010·Current Psychiatry Reports·Aryeh I Herman, Mehmet Sofuoglu
Feb 1, 2012·The Journal of Laryngology and Otology·R S NattA C Swift
Aug 18, 2012·Journal of Child and Adolescent Psychopharmacology·Ameena IsaBarbara J Coffey
May 17, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Daniel CaldeiraCristina Sampaio
Sep 12, 2014·Vascular Health and Risk Management·James J DiNicolantonio, James H O'Keefe
May 24, 2011·Expert Opinion on Pharmacotherapy·Lorenzo Ghiadoni
Jan 10, 2012·Expert Opinion on Pharmacotherapy·Sripal Bangalore, Ludwin Ley
Sep 2, 2015·Expert Opinion on Pharmacotherapy·William J Elliott
Sep 13, 2011·Expert Opinion on Emerging Drugs·Ulrike Muscha SteckelingsMichael Bader
May 21, 2015·Clinical and Experimental Hypertension : CHE·Atsuhisa Sato, Seiichi Fukuda
Apr 25, 2014·The Medical Clinics of North America·Genji Terasaki, Douglas S Paauw
Mar 23, 2013·Progress in Cardiovascular Diseases·Brisham Harchandani, Alex Reyentovich
Mar 26, 2011·The American Journal of Medicine·Genevieve Gabb
Nov 3, 2010·The American Journal of Medicine·Victor L Serebruany
Sep 13, 2011·Head & Neck·Timothy M McCullochMichelle R Ciucci
Jan 5, 2011·British Journal of Pharmacology·Peter V Dicpinigaitis
Apr 5, 2016·Dental Clinics of North America·Robert J Weinstock, Michael P Johnson
Mar 26, 2015·Journal of the American Society of Hypertension : JASH·William J ElliottGeorge L Bakris
Apr 17, 2016·European Journal of Internal Medicine·Xavier HumbertLydia Guittet
Jun 5, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Stefano Taddei, L Bortolotto
May 3, 2013·Evidence-based Medicine·Massimo Volpe, Giuliano Tocci
Jul 15, 2016·Evidence-based Complementary and Alternative Medicine : ECAM·Soobin JangSeong-Gyu Ko
Oct 22, 2016·European Journal of Internal Medicine·X HumbertS Fedrizzi
Aug 9, 2015·Journal of Health Services Research & Policy·Giulio Formoso, Marco Lombardi
Feb 15, 2018·The New England Journal of Medicine·Sandra J Taler
Oct 28, 2017·Archives of Disease in Childhood·Marijke van der MeulenSaskia N de Wildt
Oct 27, 2017·Expert Opinion on Drug Safety·William J Elliott, Evgeny A Bistrika
Aug 20, 2011·The Annals of Pharmacotherapy·Jennifer TjiaTerry S Field
Nov 18, 2018·Clinical Drug Investigation·Gideon Koren, Ari Nachmani
Jan 16, 2010·AAPS PharmSciTech·Koos C van der SteenDirk M Barends
Jul 15, 2015·AAPS PharmSciTech·Chaitanya Yogananda GujjarVallabh Subashrao Deulkar
Sep 29, 2019·Current Medical Research and Opinion·Sarah E HoldenCraig J Currie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.